Patents by Inventor Samuel K. Kulp

Samuel K. Kulp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9174951
    Abstract: Thiazolidinedione compounds and pharmaceutically acceptable salts thereof are described. The compounds can be used in methods of treating cancer in a subject by administering to the subject a therapeutically effective amount of the compound. The compounds can also be used in methods of inhibiting glucose uptake in a cell by contacting the cell with the compound.
    Type: Grant
    Filed: March 28, 2013
    Date of Patent: November 3, 2015
    Assignee: OHIO STATE INNOVATION FOUNDATION
    Inventors: Ching-Shih Chen, Dasheng Wang, Samuel K. Kulp
  • Patent number: 9079899
    Abstract: A method of treating infection by Staphylococcus in a subject by administering a pharmaceutical composition including a celecoxib derivative of formula I or a pharmaceutically acceptable salt thereof is described. The preparation of numerous celecoxib derivatives for testing as potential anti-staphylococcal agents is also described.
    Type: Grant
    Filed: October 31, 2011
    Date of Patent: July 14, 2015
    Assignee: THE OHIO STATE UNIVERSITY
    Inventors: Ching-Shih Chen, Hao-Chieh Chiu, Dasheng Wang, Samuel K. Kulp
  • Publication number: 20150051255
    Abstract: Thiazolidinedione compounds and pharmaceutically acceptable salts thereof are described. The compounds can be used in methods of treating cancer in a subject by administering to the subject a therapeutically effective amount of the compound. The compounds can also be used in methods of inhibiting glucose uptake in a cell by contacting the cell with the compound.
    Type: Application
    Filed: March 28, 2013
    Publication date: February 19, 2015
    Applicant: The Ohio State University Research Foundation
    Inventors: Ching-Shih Chen, Dasheng Wang, Samuel K. Kulp
  • Patent number: 8658647
    Abstract: A number of compounds and use of the compounds in a method for treating or preventing cancer in a subject by administering to the subject a pharmaceutical composition including a compound of formula I or a pharmaceutically acceptable salt thereof are described. The compounds can also be used to inhibit integrin-linked kinase in a cell, which has an effect on the Akt signaling pathway.
    Type: Grant
    Filed: November 21, 2011
    Date of Patent: February 25, 2014
    Assignee: The Ohio State University Research Foundation
    Inventors: Ching-Shih Chen, Su-Lin Lee, Samuel K. Kulp
  • Publication number: 20140031388
    Abstract: Anticancer compounds according to formula I are described herein. wherein R1, R2, R3 and R4 are selected from H, CH3, OH, SH, OCH3, NHR?, halogen, CF3, N-linked pyrrolidine, and SO2NHR?, or any combination thereof; R5 is an alkyl, alkenyl, or alkaryl group including from 4 to 11 carbons, X is selected from CH2, CHOH, C?O, S?O, O?S?O, and an oxetane ring, Y is selected from CH2, O, and NH, and R? is a H, aryl, or a lower alkyl group, or pharmaceutically acceptable salts thereof. The compounds have been shown to facilitate site-specific dephosphorylation of Akt at Ser-473, thereby inactivating Akt and decreasing dysregulation of Akt signaling that can occur in cancer cells.
    Type: Application
    Filed: July 26, 2013
    Publication date: January 30, 2014
    Inventors: Ching-Shih Chen, Dasheng Wang, Samuel K. Kulp
  • Publication number: 20130289004
    Abstract: A method of treating infection by Staphylococcus in a subject by administering a pharmaceutical composition including a celecoxib derivative of formula I or a pharmaceutically acceptable salt thereof is described. The preparation of numerous celecoxib derivatives for testing as potential anti-staphylococcal agents is also described.
    Type: Application
    Filed: October 31, 2011
    Publication date: October 31, 2013
    Applicant: The Ohio State University Research Foundation
    Inventors: Ching-Shih Chen, Hao-Chieh Chiu, Dasheng Wang, Samuel K. Kulp
  • Patent number: 8461362
    Abstract: Tocopheryl succinate derivatives according to formula I: are described. These compounds increase the activity of protein phosphatase 2A, can be included in pharmaceutical compositions, and can be used for the treatment of androgen receptor-dependent cancers such as prostate cancer.
    Type: Grant
    Filed: April 13, 2010
    Date of Patent: June 11, 2013
    Assignee: The Ohio State University Research Foundation
    Inventors: Ching-Shih Chen, Dasheng Wang, Samuel K. Kulp
  • Patent number: 8362071
    Abstract: Vitamin E succinate derivatives according to formula I: are described. These compounds can be included in pharmaceutical compositions, and can be used for the treatment of cancers such as metastatic cancer and as antiadhesive agents.
    Type: Grant
    Filed: April 16, 2010
    Date of Patent: January 29, 2013
    Assignee: The Ohio State University Research Foundation
    Inventors: Ching-Shih Chen, Dasheng Wang, Samuel K. Kulp
  • Patent number: 8309768
    Abstract: A number of FTY720-derived compounds with antitumor activity are described. These compounds include the compounds of formula I: wherein R1 is independently selected from the group consisting of hydrogen, methyl. methoxy, and hydroxyl; R2 is independently selected from the group consisting of hydrogen, methoxy, and hydroxyl; R3 is independently selected from the group consisting of alkyl and cyclo-alkyl; and n is independently selected from 0 to 6. The compounds have lower immunosuppressive side effects as a result of not being phosphorylated by sphingosine kinase 2.
    Type: Grant
    Filed: November 29, 2011
    Date of Patent: November 13, 2012
    Assignee: The Ohio State University Research Foundation
    Inventors: Ching-Shih Chen, Samuel K. Kulp, Dasheng Wang, John C. Byrd, Natarajan Muthusamy
  • Publication number: 20120142702
    Abstract: A number of compounds and use of the compounds in a method for treating or preventing cancer in a subject by administering to the subject a pharmaceutical composition including a compound of formula I or a pharmaceutically acceptable salt thereof are described. The compounds can also be used to inhibit integrin-linked kinase in a cell, which has an effect on the Akt signaling pathway.
    Type: Application
    Filed: November 21, 2011
    Publication date: June 7, 2012
    Applicant: The Ohio State University Research Foundation
    Inventors: Ching-Shih Chen, Su-Lin Lee, Samuel K. Kulp
  • Publication number: 20120136063
    Abstract: A number of FTY720-derived compounds with antitumor activity are described. These compounds include the compounds of formula I: wherein R1 is independently selected from the group consisting of hydrogen, methyl. methoxy, and hydroxyl; R2 is independently selected from the group consisting of hydrogen, methoxy, and hydroxyl; R3 is independently selected from the group consisting of alkyl and cyclo-alkyl; and n is independently selected from 0 to 6. The compounds have lower immunosuppressive side effects as a result of not being phosphorylated by sphingosine kinase 2.
    Type: Application
    Filed: November 29, 2011
    Publication date: May 31, 2012
    Applicant: The Ohio State University Research Foundation
    Inventors: Ching-Shih Chen, Samuel K. Kulp, Dasheng Wang, John C. Byrd, Natarajan Muthusamy
  • Publication number: 20120108823
    Abstract: A series of celecoxib derivatives defined by Formula I: were prepared and evaluated for their ability to inhibit the gram-negative bacteria Francisella tularensis. Pharmaceutical compositions including celecoxib derivatives and their use in methods for treating or preventing infection by Francisella tularensis in a subject are described.
    Type: Application
    Filed: April 22, 2009
    Publication date: May 3, 2012
    Applicant: THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION
    Inventors: Ching-Shih Chen, Hao-Shieh Chiu, Samuel K. Kulp
  • Publication number: 20100267673
    Abstract: Tocopheryl succinate derivatives according to formula I: are described. These compounds increase the activity of protein phosphatase 2A, can be included in pharmaceutical compositions, and can be used for the treatment of androgen receptor-dependent cancers such as prostate cancer.
    Type: Application
    Filed: April 13, 2010
    Publication date: October 21, 2010
    Applicant: THE OHIO SATE UNIVERSITY RESEARCH FOUNDATION
    Inventors: Ching-Shih Chen, Dasheng Wang, Samuel K. Kulp
  • Publication number: 20100267820
    Abstract: Vitamin E succinate derivatives according to formula I: are described. These compounds can be included in pharmaceutical compositions, and can be used for the treatment of cancers such as metastatic cancer and as antiadhesive agents.
    Type: Application
    Filed: April 16, 2010
    Publication date: October 21, 2010
    Applicant: THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION
    Inventors: Ching-Shih Chen, Dasheng Wang, Samuel K. Kulp